K

F

F-Prime Capital

Crunchbase
Pitchbook
Crunchbase

Deals on record

28

Common Fundraising Type

Series A

G
Galatea Bio

AI-driven • Genomic research

Stanford logo
Helios Digital Ventures logo
HBM Genomics logo
Founders Collective logo

Galatea Bio is a biotechnology company that uses AI-driven genomic research and clinical genetic testing to advance precision medicine and improve genetic risk analysis, biomarker discovery, and clinical trials optimization.

Equity
$25M
03/27/2025
Article
B
Bluebird Kids Health

Pediatric care • Value-based model

Juxtapose logo
F Prime logo
AIF logo
.406 Ventures logo

Bluebird Kids Health provides a value-based pediatric care model with 24/7 access to pediatricians and virtual care services.

Equity
$31.5M
03/05/2025
Article
E
Ethena

Synthetic stablecoin • USDe

Franklin Templeton logo
F-Prime Capital logo

Ethena develops synthetic stablecoins, including USDe and the upcoming iUSDe, designed to maintain value stability through innovative financial mechanisms rather than direct fiat backing.

Equity
$100M
02/24/2025
Article
E
Eleos

AI in Behavioral Health • CareOps Automation

Greenfield Partners logo
Union Tech Ventures logo
Michael & Susan Dell Foundation logo
Menlo Ventures logo

Eleos Health specializes in CareOps Automation, using AI to automate documentation and clinical insights for behavioral health conversations, aiming to reduce operational burden on providers and improve care quality.

Series C
$60M
01/22/2025
Article
R
RhyGaze

Gene therapy • Retinal diseases

GV logo
Novartis logo
F-Prime Capital logo
BioGeneration Ventures logo

RhyGaze is a biotechnology company developing gene therapies for vision restoration in retinal diseases.

Series A
$86M
01/10/2025
Article
L
Leyden Labs

Mucosal Protection • Intranasal Antibody

ClavystBio logo
Qiming Venture Partners logo
Polaris Partners logo
GV logo

Leyden Labs develops non-vaccine intranasal antibody treatments to protect against respiratory viruses like influenza and coronaviruses.

Equity
$70M
01/09/2025
Article
T
Tenvie Therapeutics

Biotechnology • Therapeutics

Mubadala Capital logo
F-Prime Capital logo
ARCH Venture Partners logo

Tenvie Therapeutics is a biotechnology company developing small molecule therapeutics for neurological, cardiometabolic, and ophthalmic diseases.

Equity
$200M
01/08/2025
Article
T
TripSuite

AI-powered • CRM

F-Prime Capital logo
Thayer Ventures logo
Bienville Capital Management logo

TripSuite provides an AI-powered software platform that streamlines workflows and improves efficiency for travel agencies by integrating CRM, commission tracking, accounting, and analytics.

Seed
$5M
12/19/2024
Article
n
nChroma Bio

Epigenetic editing • Genetic medicines

Wilson Sonsini Goodrich & Rosati logo
Wellington Management logo
T. Rowe Price logo
Sofinnova Partners logo

nChroma Bio develops innovative genetic medicines using epigenetic editing and non-viral delivery technologies to treat chronic hepatitis B and D.

Equity
$75M
12/11/2024
Article
A
Albert Invent

AI • Chemical R&D

Coatue logo
TCV logo
Index Ventures logo
Homebrew logo

Albert Invent provides an AI-driven platform to optimize chemical R&D processes, offering tools like real-time toxicology predictions and molecular property forecasting for chemists.

Series A
$22.5M
12/11/2024
Article
Z
Zenflow

Medical device • Minimally invasive

Medical Technology Venture Partners logo
Invus Opportunities logo
F-Prime Capital logo
Cook Medical logo

Zenflow, Inc. develops minimally invasive medical devices for treating urinary obstruction caused by benign prostatic hyperplasia (BPH).

Series C
$24M
11/18/2024
Article
N
Notabene

Crypto • Anti-money laundering

Y Combinator logo
Wintermute logo
Signature Ventures logo
Nextblock logo

Notabene provides a platform for crypto anti-money laundering compliance, helping companies adhere to global AML regulations like the Financial Action Task Force's "Travel Rule."

Series B
$14.5M
11/12/2024
Article
A
AvenCell

Cell therapy • CAR-T

Novo Holdings logo
F-Prime Capital logo
NYBC Ventures logo
Piper Heartland Healthcare Capital logo

AvenCell Therapeutics, Inc. develops a Universal Switchable CAR-T cell therapy platform for treating hematologic malignancies and autoimmune diseases.

Series B
$112M
10/22/2024
Article
S
Shift Bioscience

AI-driven • Cell simulation

Kindred Capital logo
F-Prime Capital logo
BGF logo

Shift Bioscience is a biotech company that uses an AI-driven cell simulation platform to identify rejuvenation genes for developing therapeutics for age-related diseases.

Seed
$16.3M
10/15/2024
Article
S
SPRY Therapeutics

SaaS • Physical therapy

Together Fund logo
Flourish Ventures logo
F-Prime Capital logo
Eight Roads Ventures logo

SPRY Therapeutics provides an AI-driven SaaS platform for physical therapy professionals to manage clinics, enhance billing, and improve patient engagement.

Equity
$15M
10/11/2024
Article
R
Rippl

Virtual dementia care • AI technology

Kin Ventures logo
Mass General Brigham Ventures logo
JSL Health logo
GV logo

Rippl is a virtual dementia care company focused on providing tech-driven care solutions and expanding its network of healthcare providers for senior-focused behavioral health.

Series A
$23M
10/09/2024
Article
C
Centivo

Healthcare • Affordability

Trinity Capital logo
Morgan Health logo
MemorialCare logo
Ingleside Investors logo

Centivo is a healthcare company focused on making high-quality healthcare more affordable for employers and their employees by reducing out-of-pocket costs.

Hybrid
$75M
09/26/2024
Article
Q
Quantum Circuits

Quantum computers • High-fidelity qubits

Tribeca Venture Partners logo
Tao Capital Partners logo
Sequoia Capital logo
Osage University Partners logo

Quantum Circuits develops high-fidelity quantum computers with intrinsic error detection and handling.

Series B
$60M
08/16/2024
Article
C
Chaos Labs

Onchain • Risk management

Wintermute Ventures logo
Spartan Capital logo
Slow Ventures logo
PayPal Ventures logo

Chaos Labs is an NYC-based company that provides onchain risk management and economic security for crypto protocols.

Series A
$55M
08/16/2024
Article
S
Shinobi Therapeutics

Biotechnology • IPS-T cell therapy

F-Prime Capital logo
EQT Life Sciences logo
JIC Venture Growth Investments logo
Fast Track Initiative logo

Shinobi Therapeutics is a biotech company developing off-the-shelf, immune-evasive, induced pluripotent stem cell (iPSC)-derived cell therapies for GPC3+ solid tumor cancers.

Series A
$51M
12/12/2023
Article
A
ARTBIO

Radiopharmaceuticals • AlphaDirect™ Technology

Third Rock Ventures logo
Omega Funds logo
F-Prime Capital logo

ARTBIO is a clinical-stage biotech firm specializing in developing alpha radioligand therapies for cancer treatment, currently advancing its proprietary technology and lead prostate cancer program through clinical trials.

Series A
$90M
12/07/2023
Article
T
T-Therapeutics

Biotech • TCR Therapeutics

Sofinnova Partners logo
University of Cambridge logo
Sanofi Ventures logo
F-Prime Capital logo

T-Therapeutics is a biotech firm specializing in developing TCR therapeutics for cancer and inflammatory disorders using their proprietary OpTiMus® platform.

Series A
$59.6M
11/16/2023
Article
E
Eleos Health

AI in Behavioral Health • CareOps Automation

Menlo Ventures logo
SamsungNEXT logo
lool ventures logo
ION logo

Eleos Health specializes in CareOps Automation, using AI to automate documentation and clinical insights for behavioral health conversations, aiming to reduce operational burden on providers and improve care quality.

Series B
$40M
11/08/2023
Article
W
Warmly

Sales leads • Autonomous sales platform

Zoom Ventures logo
NFX logo
Maven Ventures logo
F-Prime Capital logo

Warmly is an autonomous sales platform that uses intent data to identify and connect with potential customers, providing warm leads for sales departments.

Series A
$11M
10/19/2023
Article
A
Avalyn Pharma

Biopharmaceutical • Respiratory Diseases

Perceptive Xontogeny Venture Funds logo
Wellington Management logo
Vida Ventures logo
T. Rowe Price Associates logo

Avalyn Pharma is a biopharmaceutical company that develops inhalation therapies for rare respiratory diseases, including pulmonary fibrosis and other interstitial lung diseases, with a focus on creating new inhaled formulations of approved medicines.

Series C
$175M
09/27/2023
Article
D
Doceree

Healthcare Communications • Pharmaceutical Marketing

Creaegis logo
Eight Roads Ventures logo
F-Prime Capital logo

Doceree is a global network that provides programmatic messaging platforms exclusively for physicians, enabling pharmaceutical and life sciences companies and healthcare media agencies to reach healthcare professionals within their digital workflows, and introduce solutions to improve patient health outcomes.

Series B
$35M
09/27/2023
Article
A
Adela

Blood Testing • Cancer Detection

RA Capital Management logo
OrbiMed logo
Labcorp logo
F-Prime Capital logo

Adela is a healthcare technology company that specializes in blood testing for early cancer detection and minimal residual disease monitoring using a genome-wide methylome enrichment platform.

Equity
$48M
09/26/2023
Article
B
Better Life Partners

Healthcare Technology • Substance Use Disorder Treatment

aMoon logo
F-Prime Capital logo
.406 Ventures logo

Better Life Partners is a Boston-based healthcare company that provides a technology-enabled care model for individuals with substance use disorders, offering services such as specialty treatment, mental and physical healthcare, and care coordination.

Series B
$26.5M
08/29/2023
Article